NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), a leading international biopharmaceutical company, today announce that NeuroSolutions is presenting further pivotal pre-clinical efficacy data for NSL043/SD118. This investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinical studies and is now ready for Phase II studies.
The data presented demonstrate that NSL-043/SD-118 reverses static allodynia and inhibits spontaneous ectopic discharge in the streptozotocin-induced diabetic neuropathy and chronic constriction injury models of neuropathic hypersensitivity and suggest that this compound may be effective in treating neuropathic pain in man.
NSL-043/SD118 is being jointly developed by NeuroDiscovery and its wholly owned subsidiary NeuroSolutions Ltd under a collaboration agreement with Sosei concluded in June 2006. NSL-043/SD118 was previously under clinical investigation in Japan for a different indication and demonstrated a potential new use as an oral therapy in neuropathic pain through a re-profiling collaboration.
Dr Chris Moyses, Group Chief Executive of NeuroDiscovery, commented: “we are delighted to announce these important observations which represent a valuable endorsement of the Company’s approach to discovering first-in-class compounds that are clearly differentiated from existing therapeutics used in the management of neuropathic and inflammatory pain.”
Mr Shinichi Tamura, CEO Sosei Group added: “we are pleased to have collaborated with NeuroDiscovery on this project and to have generated a clinical asset in an area of significant unmet medical need.”
Neuroscience 2008, the Society for Neuroscience's 38th annual meeting, is scheduled for Nov. 15 to 19 in Washington, DC. Each year SfN provides the premier venue for neuroscientists to share research findings. SfN's annual meeting draws diverse attendees from all over the world.